156094-63-2

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(Bromomethyl)-6-methoxypyridine is used as an intermediate in the synthesis of pharmaceuticals for its reactivity and ability to form new compounds that can be used in drug development.
Used in Agrochemical Production:
This chemical compound is also utilized as an intermediate in the production of agrochemicals, where its properties can be leveraged to create effective products for agricultural applications.
Used in Organic Chemical Production:
2-(Bromomethyl)-6-methoxypyridine serves as a building block in the synthesis of other organic chemicals, contributing to the diversity of chemical products available for various industries.
Used in Research Applications:
In research settings, 2-(broMoMethyl)-6-Methoxypyridine is employed for studying chemical reactions and exploring new methods of synthesis, given its unique structure and reactivity.
Used in Chemical Reactions:
Due to the presence of the bromomethyl group, 2-(Bromomethyl)-6-methoxypyridine is used in various chemical reactions to form different types of organic compounds, showcasing its versatility in organic synthesis.
Proper handling and storage are crucial for 2-(Bromomethyl)-6-methoxypyridine due to its classification as a hazardous chemical, ensuring safety in its applications across different industries.

Upstream product

• 63071-03-4 2-methoxy-6-methyl-pyridine 
• 54221-96-4 6-methoxypyridine-2-carbaldehyde 
• 26893-73-2 6-methoxypyridine-2-carboxylic acid 
• 19621-92-2 6-Hydroxypicolinic acid 
• 26256-72-4 6-methoxy-pyridine-2-carboxylic acid methyl ester 
• 63071-12-5 (6-methoxy-pyridin-2-yl)-methanol 
• 3279-76-3 6-hydroxy-2-methylpyridine 

Downstream Products

• 1000512-48-0 2‐(6‐methoxypyridin‐2‐yl)acetonitrile 
• 1361225-14-0 1,1,1,3,3,3-hexafluoro-2-(4-(2-((6-methoxy-2-pyridinyl)methyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 1361225-15-1 ethyl N-(diphenylmethylidene)-3-(6-methoxy-2-pyridinyl)alaninate 

Relevant academic research and scientific papers

Photoisomerization and photoinduced intramolecular hydrogen atom transfer of 2-[2-(2-pyrrolyl)ethenyl]pyridine derivatives

Introduction of an electron-donating methoxy group to 2-[2-(2-pyrrolyl)ethenyl]pyridine, which undergoes photoinduced intramolecular hydrogen atom transfer and one-way trans-to-cis photoisomerization, induced significant changes in these photochemical beh

SMALL MOLECULE CORRECTORS OF MAMMALIAN SLC6A8 FUNCTION

Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with mutation in a protein.

Azacyclo diketone compound and preparation method thereof

The invention provides an azacyclo diketone compound, which is a compound represented by the following structure defined in the specification, or a pharmaceutically acceptable salt thereof. The invention provides a compound having an inhibitory activity on influenza (flu) virus proliferation, particularly on influenza-related cap-dependent endonuclease to inhibit influenza virus proliferation so as to treat or prevent influenza. The present invention relates to a substituted azacyclo diketone compound having inhibitory activity on cap-dependent endonuclease, and a pharmaceutical composition containing the substituted azacyclo diketone compound.

Azacycle diketone compound and preparation method thereof (by machine translation)

The invention provides a azacyclodiketone compound which is characterized by being a compound represented by the following structure. The compound has inhibitory activity on cap-dependent endonuclease. (by machine translation)

OX2R COMPOUNDS

Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.

HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME

Disclosed are compounds of formula (I): or a pharmaceutically acceptable salt thereof; wherein Y, Ra, Ra', Rc, Rf, X2, Rd, Rd', Re, Re', m, and G have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry, useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular and neurodegenerative diseases or disorders.

SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES

The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS

Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4 and R5 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain.

Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction

Compounds of the formulae (IA) and (IB): wherein R1is C1to C3alkyl optionally substituted with phenyl, Het or a N-linked heterocyclic group selected from piperidinyl and morpholinyl; wherein said phenyl group is optionally substituted by one or more substitutents selected from C1to C4alkoxy; halo; CN; CF3; OCF3or C1to C4alkyl wherein said C1to C4alkyl group is optionally substituted by C1to C4haloalkyl or haloalkoxy either of which is substituted by one or more halo atoms; R2is C1to C6alkyl and R13is OR3or NR5R6, or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity are potent and selective inhibitors of type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).

Functionalisation of 2-methoxy-6-methylpyridine

Selective bromination of 2-methoxy-6-methylpyridine 2 afforded 5-bromo-2- methoxy-6-methylpyridine 8. Deprotonation of this pyridine derivative in benzylic position or lithium-bromine exchange allowed the regio-selective introduction of various electrophiles.